Pioneering the future of regenerative medicine through stem cell technology
香港再生醫學有限公司(Hong Kong Regen Medtech Limited “HKRM”)於2019年成立並落戶於香港科學園的幹細胞生物科技公司,致力透過幹細胞的技術實現健康和長壽的願景。建立一個融合平台,利用幹細胞的新技術及潛在的開發、制造和提供跨平台治療的幹細胞產品。
香港再生醫學致力成為亞洲首間符合國際最高標準 - 國際醫藥品稽查協約組織 (Pharmaceutical Inspection Co-operation Scheme (PIC/S)) 的私營幹細胞療法制品制造商,為區內病人提供最高質素的幹細胞療法制品。
To help people achieve their desire for healthy longevity through stem cell therapies
HKRM’s founding and governance leadership combines cross-sector business experience with a long-term industry vision to support the clinical translation of regenerative medicine and stem cell innovation.
Mr. Cheng Chi-Heng, Conroy is Chairman and Co-Founder of HKRM. He is Vice-chairman and Executive Director of Chow Tai Fook Jewellery Group Limited, and a director of Chow Tai Fook (Holding) Limited and Chow Tai Fook Enterprises Limited. He also serves as a Non-executive Director of New World Development Company Limited. With extensive experience in corporate strategy, transformation, investment and cross-sector business development, Mr. Cheng supports HKRM’s mission to advance regenerative medicine and stem cell innovation in Hong Kong and beyond.
Mr. Sy Ming Yiu, Stanley is Co-Founder and CEO of HKRM. He has more than a decade of experience in biotechnology, oncology diagnostics and innovative healthcare. A biomedical engineering graduate of The Chinese University of Hong Kong, he previously worked at Prince of Wales Hospital and later led Sanomics Limited as Chief Executive Officer and Executive Director. He also founded Aurora Tele-Oncology Limited and Alpha Life Company Limited. At HKRM, Mr. Sy drives business strategy, clinical translation and partnerships to advance stem cell research and applications.
Learn more about HKRM's innovative stem cell therapies and partnership opportunities
联络我们